Literature DB >> 20003923

Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Tilo Senger1, Lysann Schädlich, Sonja Textor, Corinna Klein, Kristina M Michael, Christopher B Buck, Lutz Gissmann.   

Abstract

The potential as prophylactic vaccines of L1-based particles from cutaneous genus alpha human papillomavirus (HPV) types has not been assessed so far. However, there is a high medical need for such vaccines since HPV-induced skin warts represent a major burden for children and for immunocompromised adults, such as organ transplant recipients. In this study, we have examined the immunogenicity of capsomeres and virus-like particles (VLPs) from HPV types 2, 27, and 57, the most frequent causative agents of skin warts. Immunization of mice induced immune responses resembling those observed upon vaccination with HPV 16 L1-based antigens. The antibody responses were cross-reactive but type-restricted in their neutralizing capacities. Application of adjuvant led to an enhanced potential to neutralize the respective immunogen type but did not improve cross-neutralization. Vaccination with capsomeres and VLPs from all four analyzed HPV types induced robust IFNgamma-associated T-cell activation. Immunization with mixed VLPs from HPV types 2, 27, and 57 triggered an antibody response similar to that after single-type immunization and capable of efficiently neutralizing all three types. Our results imply that vaccination with combinations of VLPs from cutaneous HPV types constitutes a promising strategy to prevent HPV-induced skin lesions. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20003923      PMCID: PMC7416602          DOI: 10.1016/j.vaccine.2009.11.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  66 in total

1.  Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo.

Authors:  Bakhos A Tannous; Dong-Eog Kim; Juliet L Fernandez; Ralph Weissleder; Xandra O Breakefield
Journal:  Mol Ther       Date:  2005-03       Impact factor: 11.454

2.  Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

Authors:  X S Chen; G Casini; S C Harrison; R L Garcea
Journal:  J Mol Biol       Date:  2001-03-16       Impact factor: 5.469

3.  Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels.

Authors:  Kerstin Dell; Robert Koesters; Michael Linnebacher; Corinna Klein; Lutz Gissmann
Journal:  Vaccine       Date:  2005-12-13       Impact factor: 3.641

4.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.

Authors:  R S Lowe; D R Brown; J T Bryan; J C Cook; H A George; K J Hofmann; W M Hurni; J G Joyce; E D Lehman; H Z Markus; M P Neeper; L D Schultz; A R Shaw; K U Jansen
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.

Authors:  N D Christensen; N M Cladel; C A Reed; L R Budgeon; M E Embers; D M Skulsky; W L McClements; S W Ludmerer; K U Jansen
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

6.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 7.  Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.

Authors:  Andrea Duchini; John A Goss; Saul Karpen; Paul J Pockros
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

8.  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

Authors:  Alba-Lucia Combita; Antoine Touzé; Latifa Bousarghin; Neil D Christensen; Pierre Coursaget
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Identification of an immunologically distinct papillomavirus from lesions of epidermodysplasia verruciformis.

Authors:  F Pass; M Reissig; K V Shah; M Eisinger; G Orth
Journal:  J Natl Cancer Inst       Date:  1977-10       Impact factor: 13.506

10.  Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant.

Authors:  Wanda Ruiz; William L McClements; Kathrin U Jansen; Mark T Esser
Journal:  J Immune Based Ther Vaccines       Date:  2005-04-20
View more
  12 in total

1.  Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.

Authors:  Hai-Bo Liu; Pankaj Kumar Chaturvedi; Gantumur Battogtokh; Hyo Joo Bang; In-Wook Kim; Yong-Wan Kim; Kye-Shin Park; Woong Shick Ahn
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

2.  [Clinical algorithm of cutaneous extragenital wart treatment].

Authors:  A Rübben
Journal:  Hautarzt       Date:  2011-01       Impact factor: 0.751

3.  Evaluation of a novel multiplex human papillomavirus (HPV) genotyping assay for HPV types in skin warts.

Authors:  Markus Schmitt; Maurits N C de Koning; Just A H Eekhof; Wim G V Quint; Michael Pawlita
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

4.  Design strategies to address the effect of hydrophobic epitope on stability and in vitro assembly of modular virus-like particle.

Authors:  Alemu Tekewe; Natalie K Connors; Anton P J Middelberg; Linda H L Lua
Journal:  Protein Sci       Date:  2016-06-13       Impact factor: 6.725

Review 5.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

Review 6.  HPV vaccination for prevention of skin cancer.

Authors:  Sabrina E Vinzón; Frank Rösl
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.

Authors:  Arjun Seth; Fiona K Ritchie; Nani Wibowo; Linda H L Lua; Anton P J Middelberg
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

8.  Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.

Authors:  Yan Liu; Junmei Zhou; Zhizhun Yu; Danyun Fang; Chunyun Fu; Xun Zhu; Zhenjian He; Huijun Yan; Lifang Jiang
Journal:  BMC Microbiol       Date:  2014-12-18       Impact factor: 3.605

9.  Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).

Authors:  Bettina Huber; Christina Schellenbacher; Saeed Shafti-Keramat; Christoph Jindra; Neil Christensen; Reinhard Kirnbauer
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

10.  Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Authors:  Kihyuck Kwak; Rosie Jiang; Joshua W Wang; Subhashini Jagu; Reinhard Kirnbauer; Richard B S Roden
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.